inclisiran
AssetOligonucleotideAlso 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Inclisiran Sodium, Inclisiran sodium 300 mg, KJX839
siRNA that targets PCSK9 mRNA to lower LDL cholesterol.
- Stage
- Phase 3
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- Indications
- 29
- Trials
- 43
- Developers
- 2
Indications
29Acute coronary syndrome
Phase 3NOT_YET_RECRUITINGNCT07684469clinicaltrials.gov7 Oct 2026
Ascvd
Phase 3COMPLETEDNCT03400800clinicaltrials.gov7 Oct 2026
Atherosclerotic cardiovascular disease
Phase 3ACTIVE_NOT_RECRUITINGNCT05030428clinicaltrials.gov7 Oct 2026
26 more
- Targets and what it contains2
- Owner and partners2
- Trials43
- Evidence for its targets3
- Competitors12
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 24 sources